Assessment of functional status in patients with invasive carcinoma of the urothelial tract

Urologic Oncology

Volumn 2, Issue 2, 1996, Pages 43-51

  Kamby, Claus ^a   Sengeløv, Lisa ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

methodologic aspects; Performance status; urothelial cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; PRIORITY JOURNAL; RELIABILITY; UROGENITAL TRACT CANCER;

EID: 0030110936     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(96)00049-X     Document Type: Article

References (41)

1. 1. Karnofsky DA, Abelmann WH, Graver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948;1:634-56.
2. 2. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results in cancer treatment. Cancer 1981;46:47-207.
3. 3. World Health Organization. Handbook for reporting results of cancer treatment. WHO, Geneva, 1979.
4. 4. Zubrod CG, Schneiderman M, Frei E. Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960;11:7-33.
5. 5. Orr ST, Aisner J. Performance status assessment among oncology patients: A review. Cancer Treat Rep 1986;70:1423-9.
6. 6. Verger E, Salamero M, Conill C. Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? Eur J Cancer 1992;28A: 1328-30.
7. 7. Yates JW, Chalmer B, Mckegney FP. Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer 1980;45:2220-4.
8. 8. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: Reliability, validity and guidelines. J Clin Oncol 1984;2:187-93.
9. 9. Cohen MH, Makuch R, Johnston-Early A, Ihde DC, Bunn PA, Fossieck BE, Minna JD. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981;65: 187-95.
10. 10. Sengeløv L, Kamby C, Schou G, Maase Hvd. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer 1994;74:123-33.
11. 11. Geertsen P, Sengeløv L, Larsen SK, Maase Hvd. A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell cancer of the urothelium. Eur J Cancer 1993;29A:347-50.
12. 12. Sengeløv L, Nielsen OS, Kamby C, Maase HVD. Platinum analogue combination chemotherapy - cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial carcinoma - a phase two trial with evaluation of prognostic factors. Cancer 1995;76:1797-803.
13. 13. Sengeløv L, Kamby C, Maase Hvd. Anatomical distribution of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial cell carcinoma. J Urol 1996;155:111-4.
14. 14. Sengeløv L, Nielsen OS, Kamby C, Maase Hvd. Systemic mitomycin C as second line therapy for metastatic urothelial cancer. Acta Oncol 1995;34:978-9.
15. 15. Landis JR, Koch GG. The measurements of observer agreement for categorical data. Biometrics 1977;33:150-74.
16. 16. Altman DG. Practical statistics for medical research. Chapman & Hall, London, 1993.
17. 17. Espinoza P, Ducot B, Pelletier G, Attali P, Buffet C, David B, Labayle D, Etienne JP. Interobserver agreement in the physical diagnosis of alcoholic liver disease. Dig Dis Science 1987;32: 244-7.
18. 18. Peto R, Pike MC, Armitage P, Breslow E, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 1977;35: 1-39.
19. 19. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972;34:187-95.
20. 20. George SL. Identification and assessment of prognostic factors. Semin Oncol 1988;15:462-71.
21. 21. Rueben DB, Mor V, Hiris J. Clinical symptoms and lengths of survival in patients with terminal cancer. Arch Intern Med 1995;148:1586-91.
22. 22. Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991;67:1525-31.
23. 23. Pollack AP, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: Prognostic factors. Int J Rad Oncol Biol Phys 1994;30:267-77.
24. 24. Dunst J, Sauer R, Schrot KM, Kühn R, Wittekind C, Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: A 10-year experience. Int J Rad Oncol Biol Phys 1994;30: 261-6.
25. 25. Sell A, Jakobsen A, Nerstrøm B, Sørensen BL, Steven K, Barlebo H. Treatment of advanced bladder cancer category T2, T3 and T4. Scand J Urol Nephrol 1991;138:193-201.
26. 26. Soloway MS, Lopez AE, Patel J, Lu Y. Results of radical cystectomy for the transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 1994;73:1926-31.
27. 27. Stöckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: Long-term results of a controlled prospective study and further clinical experience. J Urol 1995; 153:47-53.
28. 28. Skinner DG, Daniels JR, Russel CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 1991; 145:459-67.
29. 29. Gospodarowich MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MAS, Thomas GM, Herman JG, Garrett PG, Chua T, Duncan W, Buckspan M, Sugar L, Rider WD. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis. J Urol 1989;142:1448-54.
30. 30. Lipponen PK, Eskelinen MJ, Nordling S. Progression and survival in transitional cell bladder cancer: A comparison of established prognostic factors, S-phase fraction and DNA ploidy. Eur J Cancer 1991;27:877-81.
31. 31. Igawa M, Ohkuchi T, Ueda M, Usui T. Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin. Cancer Chemother Pharmacol 1992;30(suppl):S77-S80.
32. 32. Boccardo F, Pace M, Guarneri D, Canobbio L, Curotto A, Martorana G. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. Cancer 1994;73:1932-6.
33. 33. Raghaven D, Shipley WU, Garnick MB, Russell PJ, Riche JP. Biology and management of bladder cancer. New Engl J Med 1990;322:1129-38.
34. 34. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler JP, Tannock IF. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma. J Clin Oncol 1992;10:1066-73.
35. 35. Geller NL, Sternberg CN, Penenberg D, Scher HI, Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991;67:1525-31.
36. 36. Khandekar JD, Elson PJ, DeWys WD, Slayton RE, Harris DT. Comparative activity and toxicity of cis-diamminedichlorplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional carcinoma of the urinary tract. J Clin Oncol 1985;3:539-45.
37. 37. Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer 1990;65:1864-6.
38. 38. Maltoni M, Nanni O, Derni MP, Fabbri L, Riva N, Maltoni R, Amadori D. Clinical prediction of survival is more accurate than the Karnofsky Performance Status in estimating life span of terminally ill cancer patients. Eur J Cancer 1994;30A:764-6.
39. 39. Parkes CM. Accuracy of prediction of survival in later stages of cancer. Br Med J 1972;2:29-31.
40. 40. Evans C, McCarthy M. Prognostic uncertainty in terminal care: Can Karnofsky Index help? Lancet 1985;i:1204-6.
41. 41. Mor V, Lalibert L, Morris JN, Wieman M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984;53:2002-7.